Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab maintenance versus observation after FCR induction in older untreated CLL patients
2007-001015-28Phase 3Completed
- Sponsor
- CHRU Tours
- Start
- Jun 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Rituximab maintenance with Observation (2 arms). Primary endpoint: 3-year progression-free survival from randomization. Started Jun 2007; status: completed.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2007-001015-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001015-28.